Mike Zaman's  Instablog

Mike Zaman
Send Message
  • Tianli Agritech (OINK) Returns To Profitability, Positive Data Of Novavax (NVAX) A(H7N9) VLP Vaccine  0 comments
    Nov 14, 2013 11:15 AM | about stocks: OINK, NVAX

    https://staticseekingalpha.a.ssl.fastly.net/uploads/2013/11/14/saupload_oink.jpg Tianli Agritech, Inc. (Nasdaq:OINK)

    After closing bell on Wednesday's trading session, OINK reported on its financial results strong top-line growth and the return to profitability after more than a year.

    For the third quarter 2013, OINK posted revenue of $8.73 million, a 33% increase year over year, gross profit of $0.90 million, compared to $0.62 million in the same period the prior year, and net income from continuing operations of $0.17 million, compared to a net loss of $1.13 million for the third quarter 2012.


    OINK is in the business of breeding, raising and selling breeder and market hogs in China and is developing a retail channel for its pork products including high-value, black hog meat.

    More about Tianli Agritech, Inc. (Nasdaq:OINK) at www.tianli-china.com


    https://staticseekingalpha.a.ssl.fastly.net/uploads/2013/11/14/saupload_nvax.jpg Novavax, Inc. (Nasdaq:NVAX)

    An outbreak of human infections with a new avian influenza A (H7N9) virus was first reported in China by the World Health Organization on April 1, 2013. The virus was detected in poultry in China as well. Most human infections are believed to have occurred after exposure to infected poultry or contaminated environments.

    During the spring of 2013, 135 H7N9 human infections were reported, the vast majority with illness onset during the month of April; 44 people died. Only 5 cases were detected over the summer. To date this fall, four human cases have been reported; all with illness onset in October.

    Most concerning about this situation is the pandemic potential of this virus. Influenza viruses constantly change and it's possible that this virus could gain the ability to spread easily and sustainably among people, triggering a global outbreak of disease.

    NVAX reported that positive clinical data for its virus-like particle (NYSE:VLP) vaccine candidate against A(H7N9) influenza were published online in the Correspondence section of The New England Journal of Medicine. The correspondence can be found at: http://www.nejm.org/doi/full/10.1056/NEJMc1313186 and will appear in the December 26, 2013 print edition.

    According to the study, conducted in 284 adult male and female subjects, NVAX's A(H7N9) VLP vaccine candidate was generally well tolerated, and the safety was in line with the company's previous findings with its influenza VLP antigens using ISCOMATRIX(NYSE:R) adjuvant.


    NVAX is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, NVAX produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

    More about Novavax, Inc. (NVAX) at www.novavax.com


    Read full disclaimer at www.mikezaman.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: OINK, NVAX
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.